NCT06877598 Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
| NCT ID | NCT06877598 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 575 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 575 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment. The primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term sexual health and well-being. As part of usual care, newly enrolled SHAReClinic patients will receive guided education modules and access to sexual health counselling at key recovery milestones. SHAReClinic seeks to expand access to sexual health care for prostate cancer patients across Canada by providing evidence-based, virtual sexual rehabilitation. Findings from this study will inform best practices in survivorship care and contribute to the development of a national standard for oncology sexual health interventions.
Eligibility Criteria
Inclusion Criteria: * Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR * Patients currently undergoing active treatment for prostate cancer OR * Patients who have undergone cancer treatment in the past 6 months * Patients who are hormone and/or chemotherapy-naïve * Patients who have access to a computer or smartphone with internet access * Patients who are 18 years of age or older Exclusion Criteria: * Patients on ADT alone as primary treatment, and/or patients on chemotherapy * Patients who lack English proficiency * Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's) * Patients with medical conditions that would preclude safe sexual activity * Patients who have had previous treatment for PCa
Contact & Investigator
Andrew Matthew, PhD. C.Psych
PRINCIPAL INVESTIGATOR
Princess Margaret Cancer Centre
Frequently Asked Questions
Who can join the NCT06877598 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06877598 currently recruiting?
Yes, NCT06877598 is actively recruiting participants. Contact the research team at steven.guirguis@uhn.ca for enrollment information.
Where is the NCT06877598 trial being conducted?
This trial is being conducted at Vancouver, Canada, Winnipeg, Canada, Barrie, Canada, Edmonton, Canada and 6 additional locations.
Who is sponsoring the NCT06877598 clinical trial?
NCT06877598 is sponsored by University Health Network, Toronto. The principal investigator is Andrew Matthew, PhD. C.Psych at Princess Margaret Cancer Centre. The trial plans to enroll 575 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.